Biomedical equipment

Tender description

Due to the pandemic situation NHSBT agreed with all current suppliers (VH Bio and Immucor) and bidders (as identified during tender excercise) to extend this existing agreement NHSBT0766 beyond 6 March 2020 by 6 months (to 31 August 2020) with two options to extend for further 3 months each (up to 12 months in total). NHSBT require Human leukocyte antigen (HLA) rapid typing system (s) to ensure compatibility between donors and recipients of solid organ transplantation (renal, liver and cardiothoracic). Building on our strengths as a national provider, NHSBT’s strategic aim is for its H&I services to become the preferred provider and supplier of choice for H&I related services in NHS England. Covid-19 pandemic is a novel, unprecedented situation that NHSBT could not have forseen at the time it awarded the contract. H&I departament is unable to continue with evaluation/valdiation stage due to staff being diverted by urgent actions to deal with Covid-19 consequences, staff being redeployed as well as unability to continue with valdiations due to current restrictions and lockdown. Due to the pandemic situation NHSBT agreed with all current suppliers (VH Bio and Immucor) and bidders (as identified during tender excercise) to extend this existing agreement NHSBT0766 beyond March 2020 by 6 months (to 31 August 2020) with two options to extend for further 3 months each (up to 12 months in total). Total value of increase in price does not exceed 50 % of the value of the original framework agreement; The nature of contract has not been changed.